Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-06-24
DOI
10.1038/s41591-022-01868-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
- (2021) Yanna Lei et al. Frontiers in Oncology
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma
- (2021) Petros Fessas et al. Cancers
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma
- (2020) Ankur Sharma et al. CELL
- Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
- (2020) Won Suk Lee et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Bystander CD4+ T cells: crossroads between innate and adaptive immunity
- (2020) Hong-Gyun Lee et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma
- (2020) Ching Ngar Wong et al. LIVER INTERNATIONAL
- multiGSEA: a GSEA-based pathway enrichment analysis for multi-omics data
- (2020) Sebastian Canzler et al. BMC BIOINFORMATICS
- Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC
- (2019) Roser Pinyol et al. CLINICAL CANCER RESEARCH
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
- (2019) David J. Pinato et al. BRITISH JOURNAL OF CANCER
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
- (2019) Marina Ruiz de Galarreta et al. Cancer Discovery
- Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation
- (2019) Pedro Berraondo et al. Cancer Discovery
- A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
- (2019) Yu-Jung Kim et al. LUNG CANCER
- Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
- (2019) Jonathan A. Trujillo et al. Journal for ImmunoTherapy of Cancer
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
- (2018) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity
- (2018) Shishir Shetty et al. Nature Reviews Gastroenterology & Hepatology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies
- (2017) Wenjun Zhang et al. LABORATORY INVESTIGATION
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
- (2015) Sachet A Shukla et al. NATURE BIOTECHNOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Hepatic Stellate Cells Preferentially Induce Foxp3+ Regulatory T Cells by Production of Retinoic Acid
- (2013) R. M. Dunham et al. JOURNAL OF IMMUNOLOGY
- Increased tumor-infiltrating CD8+Foxp3+ T lymphocytes are associated with tumor progression in human gastric cancer
- (2012) Liu-sheng Peng et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib
- (2012) A. Lachenmayer et al. CLINICAL CANCER RESEARCH
- The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature
- (2012) R. J. deLeeuw et al. CLINICAL CANCER RESEARCH
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Impact of FoxP3+ Regulatory T Cells in Relation to CD8+ T Lymphocyte Density in Human Colon Carcinomas
- (2012) Harry H. Yoon et al. PLoS One
- DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
- (2011) J.-L. Li et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- NetMHCcons: a consensus method for the major histocompatibility complex class I predictions
- (2011) Edita Karosiene et al. IMMUNOGENETICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now